Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Abstract The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enrich for patients who respond to the anti-PD1 agent pembrolizumab. To explore this im...
Main Authors: | Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M. Marincola, Alessandra Cesano |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2018-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-018-0367-1 |
Similar Items
-
A Novel TCGA-Validated, MiRNA-Based Signature for Prediction of Breast Cancer Prognosis and Survival
by: Baoxing Tian, et al.
Published: (2021-09-01) -
Identifying hub genes of papillary thyroid carcinoma in the TCGA and GEO database using bioinformatics analysis
by: Ying Wan, et al.
Published: (2020-07-01) -
A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer
by: Yingchun Liang, et al.
Published: (2021-08-01) -
Gene Expression Patterns Unveil New Insights in Papillary Thyroid Cancer
by: Mihai Saftencu, et al.
Published: (2019-08-01) -
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
by: Diane Damotte, et al.
Published: (2019-11-01)